Peptide Therapy Beyond GLP-1s, there's a whole category of peptide therapy most people never hear about when they're researching weight loss options
According to the MHRA-approved product information, these include: Nausea (very common, affecting more than 1 in 10 patients) Vomiting and diarrhoea (common, affecting up to 1 in 10 patients) Abdominal pain and constipation (common) Decreased appetite (common) These gastrointestinal symptoms typically occur during the initial weeks of treatment or following dose escalation and often diminish over time as the body adjusts to the medication
Its far better to follow your providers expert dosage recommendations
Feb 23 2021;doi:10.1007/s10741-021-10083-z Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC
Future anti-obesity agents for use in older adults Several novel AOMs are currently in development, or undergoing clinical trials, that will likely be available for the treatment of obesity soon, and have included older adult participants (Table 1)
Sonthalia S, Daulatabad D, Sarkar R
